Affordable Access

deepdyve-link
Publisher Website

Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy

Authors
  • Dhanasekaran, Renumathy1
  • Nault, Jean-Charles2, 3, 4
  • Roberts, Lewis R5
  • Zucman-Rossi, Jessica2, 6
  • 1 Division of Gastroenterology and Hepatology, Stanford University, Stanford, CA
  • 2 Inserm UMR-1162, Génomique fonctionnelle des Tumeurs solides, Université Paris Descartes, Université Paris Diderot, Université Paris 13, Labex Immuno-Oncology, Paris, France
  • 3 Liver unit, Hôpital Jean Verdier, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance-Publique Hôpitaux de Paris, Bondy, France
  • 4 Unité de Formation et de Recherche Santé Médecine et Biologie Humaine, Université Paris 13, Communauté d’Universités et Etablissements Sorbonne Paris Cité, Paris, France
  • 5 Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN
  • 6 Hôpital Europeen Georges Pompidou, F-75015, Assistance Publique-Hôpitaux de Paris, Paris, France
Type
Published Article
Journal
Gastroenterology
Publication Date
Nov 04, 2018
Volume
156
Issue
2
Pages
492–509
Identifiers
DOI: 10.1053/j.gastro.2018.11.001
PMID: 30404026
PMCID: PMC6340723
Source
PubMed Central
Keywords
Disciplines
  • Article
License
Unknown

Abstract

The pathogenesis of hepatocellular carcinoma (HCC) is poorly understood, but recent advances in genomics have increased our understanding of the mechanisms by which HBV, HCV, alcohol, fatty liver disease, and other environmental factors, such as aflatoxin, cause liver cancer. Genetic analyses of liver tissues from patients have provided important information about tumor initiation and progression. Findings from these studies can potentially be used to individualize the management of HCC. In addition to sorafenib, other multikinase inhibitors have recently been approved for treatment of HCC and the preliminary success of immunotherapy has raised hopes. Continued progress in genomic medicine could improve classification of HCCs based on their molecular features and lead to new treatments for patients with liver cancer.

Report this publication

Statistics

Seen <100 times